Bionano Genomics, Inc. — Form 10-Q
Filed August 10, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 72/100
What the filing says
Bionano appointed Albert Luderer as Interim CEO (May 6, 2026) at $600k annual base plus up to $400k bonus, plus $4k/month stipend, no equity grant. Simultaneously engaged former CEO R. Erik Holmlin as consultant at $5k/week ($260k annualized) plus $500/hr for hours >10/week, capped initially at 3 months renewable. Both agreements dated May 6–11, 2026.
Why this rating
Leadership transition is material for $12.2M company; costs ~$1M annually (both roles). Interim structure suggests uncertainty; former CEO consultant role unusual. Scale impact is significant but direction unclear without context on prior CEO or strategic plan.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.